The novel CD95-Ligand inhibitor Asunercept can inhibit apoptosis of tumor infiltrating lymphocytes and is considered a promising adjunctive therapy for multiple cancers including gliomas and myelodysplastic syndromes [58] Earlier work has shown that FAS/CD95 is implicated in steroid mediated osteonecrosis [59]; supporting a hypothesis that CD95 blockade may reduce the risk for BRONJ. Here, FAS is linked to central nervous system cancer.